[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658849":3},{"organization":4,"outcomesModule":7,"designInfo":34,"detailedDescription":40,"studyPopulation":11,"armGroups":41,"interventions":54,"overallOfficials":68,"centralContacts":72,"locations":11,"responsibleParty":78,"collaborators":11,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":82,"sex":88,"minAge":89,"maxAge":11,"enrollmentInfo":90,"targetDuration":11,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":107,"whyStopped":11,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":11},{"fullName":5,"class":6},"Genmab","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Progression-free Survival (PFS), per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, as Determined by Blinded Independent Central Review (BICR)",null,"Approximately 2 years",[14,17,19,21,23,25,27,29,32],{"measure":15,"description":11,"timeFrame":16},"Overall Survival (OS)","Approximately 4 years",{"measure":18,"description":11,"timeFrame":16},"PFS per RECIST v1.1, as Determined by Investigator Assessment",{"measure":20,"description":11,"timeFrame":16},"Progression-free Survival on the Next Line of Therapy after the First Progression (PFS2)",{"measure":22,"description":11,"timeFrame":16},"Time to First Subsequent Therapy (TFST)",{"measure":24,"description":11,"timeFrame":16},"Time to Second Subsequent Therapy (TSST)",{"measure":26,"description":11,"timeFrame":16},"Number of Participants with Cancer Antigen 125 (CA-125) Response per Gynecologic Cancer Intergroup (GCIG) Criteria",{"measure":28,"description":11,"timeFrame":16},"Number of Participants with Treatment-emergent Adverse Events (TEAEs) Including Serious Adverse Events (SAEs) and Deaths",{"measure":30,"description":11,"timeFrame":31},"Overall Change from Baseline in Global Health Status\u002FQuality of Life (GHS\u002FQoL) using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Questionnaire","Baseline up to approximately 4 years",{"measure":33,"description":11,"timeFrame":31},"Time to Deterioration (TTD) in the GHS\u002FQoL Score using the EORTC QLQ C30 Questionnaire",{"allocation":35,"interventionModel":36,"interventionModelDescription":11,"primaryPurpose":37,"observationalModel":11,"timePerspective":11,"maskingInfo":38},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":39,"maskingDescription":11,"whoMasked":11},"NONE","This is a global, randomized, open-label, Phase 3 study of Rina-S + SOC (defined as either bevacizumab maintenance or no maintenance treatment \\[observation\\]) versus SOC as maintenance treatment in participants with newly diagnosed high-grade epithelial ovarian cancer who are not considered to be a candidate for poly (ADP-ribose) polymerase (PARP) inhibitor(s) (PARPi) maintenance therapy according to local SOC.",[42,49],{"label":43,"type":44,"description":45,"interventionNames":46},"Rina-S + SOC","EXPERIMENTAL","Participants will receive Rina-S + SOC. SOC consists of either bevacizumab maintenance or no maintenance treatment (observation).",[47,48],"Drug: Rina-S","Drug: Bevacizumab",{"label":50,"type":51,"description":52,"interventionNames":53},"SOC","ACTIVE_COMPARATOR","Participants will receive SOC alone. SOC consists of either bevacizumab maintenance or no maintenance treatment (observation).",[48],[55,64],{"type":56,"name":57,"description":58,"armGroupLabels":59,"otherNames":60},"DRUG","Rina-S","Intravenous (IV) infusion.",[43],[61,62,63],"Rinatabart sesutecan","GEN1184","PRO1184",{"type":56,"name":65,"description":66,"armGroupLabels":67,"otherNames":11},"Bevacizumab","IV infusion.",[43,50],[69],{"name":70,"affiliation":5,"role":71},"Study Official","STUDY_DIRECTOR",[73],{"name":74,"role":75,"phone":76,"phoneExt":11,"email":77},"Genmab Trial Information","CONTACT","+4570202728","clinicaltrials@genmab.com",{"type":79,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100658849","phase-3-study-to-assess-the-efficacy-and-safety-of-rina-s-plus-standard-of-care-compared-to-standard-of-care-maintenance-treatment-after-first-line-1l-platinum-based-chemotherapy-in-participants-with-ovarian-cancer-100658849",false,"NCT07859215","Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer","Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment in Participants With Ovarian Cancer Following First-Line (1L) Platinum-Based Chemotherapy","RAINFOL™-10","Key Inclusion Criteria:\n\n* Newly diagnosed, histologically confirmed International Federation of Gynecology and Obstetrics (FIGO) Stage III, or IV high-grade serous or endometrioid epithelial ovarian cancer (EOC), including primary peritoneal or fallopian tube carcinoma.\n* Participants must have received 6 cycles of 1L-platinum-based chemotherapy, in accordance with applicable clinical guidelines. Up to 8 cycles are permitted based on local clinical practice.\n* Participants not deemed candidates for surgery or who have completed planned cytoreductive surgery (either primary debulking surgery \\[PDS\\] or IDS) are eligible.\n* Participants must meet one of the following criteria after completion of 1L platinum-based chemotherapy:\n\n  * Participants who received platinum-based chemotherapy with bevacizumab must have achieved complete response (CR)\u002Fno clinical evidence of disease (NED), partial response (PR), or stable disease (SD), as assessed by the investigator, and be eligible to continue bevacizumab maintenance.\n  * Participants who received platinum-based chemotherapy without bevacizumab must have achieved CR\u002FNED or PR, as assessed by the investigator, and be considered appropriate for observation.\n* Trial intervention must start within 3 to 12 weeks of the last dose of front-line chemotherapy. To avoid a treatment-free interval, bevacizumab administration should continue following the final platinum dose, provided the participant remains eligible through screening and up to the point of randomization, and no contraindications exist.\n\nKey Exclusion Criteria:\n\n* Participant has clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies, or low-grade\u002Fborderline ovarian tumors.\n* Participant has received any intervening systemic anticancer treatment excluding bevacizumab or a biosimilar administered as part of 1L treatment after the last dose of 1L platinum-based chemotherapy and before randomization.\n* Participant with any previous treatment with PARPi.\n* Participants with previous therapy with other anti-angiogenic agents different from bevacizumab or biosimilar.\n* Participant has received prior therapy with an antibody-drug conjugate (ADC) containing a topoisomerase 1 inhibitor.\n* Participant has received prior therapy with ADC targeting folate receptor alpha (FRα).\n\nNote: Other protocol-defined Inclusion and Exclusion criteria may apply.","FEMALE","18 Years",{"count":91,"type":92},602,"ESTIMATED","INTERVENTIONAL",[95],"PHASE3","This Phase 3 study will be conducted in different countries around the world with up to approximately 602 participants.\n\nThe purpose of this study is to evaluate how well Rina-S alone or in combination with an approved, standard of care (SOC) treatment works against ovarian cancer (including primary peritoneal or fallopian tube cancer) compared to the same available SOC therapy by itself, or no treatment (only monitoring).\n\nOn average, the expected trial duration for an individual participant will be approximately 4 years (depending on treatment received). The treatment length and follow-up duration will be different for every participant, but an average of 16 months of treatment is expected, followed by an estimated 29-month post treatment follow up period.\n\nParticipation in the study will require visits to the study site(s). Participants will be asked to attend 1 to 3 visits at the study clinic for each cycle (duration of cycle is 3 weeks). During site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, imaging\u002FX-rays) to monitor whether the trial treatment is safe and effective. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep receiving trial treatment for the protocol-defined study duration.",[98],"Ovarian Cancer",[98,100,101,102,103,57,104,105,65,106],"Epithelial Ovarian Cancer","Primary Peritoneal Cancer","Fallopian Tube Cancer","Rinatabart Sesutecan","Antibody-drug Conjugate","Maintenance Treatment","Folate Receptor Alpha","NOT_YET_RECRUITING","2026-09-29",{"date":110,"type":111},"2026-10-05","ACTUAL",{"date":113,"type":92},"2026-11",{"date":115,"type":92},"2034-07",{"name":5,"class":6}]